Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.

MLA

Ghilardi, G., et al. “Bendamustine Is Safe and Effective for Lymphodepletion before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 33, no. 9, Sept. 2022, pp. 916–28. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.05.521.

APA

Ghilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., Myers, J., Chen, A. I., Schachter, L., Yelton, R., Ballard, H. J., Hodges Dwinal, A., Gier, S., Victoriano, D., Weber, E., … Schuster, S. J. (2022). Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 33(9), 916–928. https://doi.org/10.1016/j.annonc.2022.05.521

Chicago

Ghilardi, G, E A Chong, J Svoboda, P Wohlfarth, S D Nasta, S Williamson, J D Landsburg, et al. 2022. “Bendamustine Is Safe and Effective for Lymphodepletion before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 33 (9): 916–28. doi:10.1016/j.annonc.2022.05.521.